Pricing Log in Create free account
Saturday 17 October 2026 Export HALO’s income statement to Excel — free account

Halozyme Therapeutics, Inc.

HALO Healthcare Biotechnology

Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

121.84 0.33 +0.27%
Market cap
$13.8B
P/E
34.6×
Fwd P/E
10.6×
Dividend yield
—
F-score
5/9
Altman Z
3.46
Beneish M
−2.59
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Halozyme Therapeutics, Inc. (HALO) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Halozyme Therapeutics, Inc. (HALO) trades at a P/E ratio of 34.6×. Over the past ten years it has ranged from 0.0× (September 2020) to 242× (December 2020); the current reading is higher than 86% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 25.8× 88.77%
FY2024 13.7× (21.82%)
FY2023 17.5× (53.10%)
FY2022 37.3× 164.02%
FY2021 14.1× (68.29%)
FY2020 44.5× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 50.5× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 22.2× 0.46%
Mar 2026 22.1× (14.16%)
Dec 2025 25.8× 71.93%
Sep 2025 15.0× 29.16%
42 more quarters

Against its own ten years

Low 0.0× High 242×
Ten-year median 14.4×
Current reading's percentile 76

P/E ratio against peers

Company P/E ratio
SMMT Summit Therapeutics PLC compare n/m
BBIO BridgeBio Pharma, Inc. compare n/m
JAZZ Jazz Pharmaceuticals PLC compare 13.8×
ASND Ascendis Pharma A/S compare 16.3×
EXEL Exelixis, Inc. compare 18.8×
HALO Halozyme Therapeutics, Inc. 34.6×
TECH Bio-Techne Corp compare 62.0×
BMRN BioMarin Pharmaceutical Inc. compare 144×
CORT Corcept Therapeutics Incorporated compare 212×
Biotechnology industry median 8.5×
Healthcare sector median 23.0×
Market median 18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on HALO